List view / Grid view
30 January 2014 | By Amgen
RUTHERFORD-2 study meets co-primary endpoints of ldl cholesterol reduction Amgen also announces results from phase 3 study with automated mini-doser completion of fifth phase 3 study forms basis for global filing plan...
28 January 2014 | By Amgen
Amgen announced that the Phase 3 LAPLACE-2 trial evaluating evolocumab in combination with statin therapy in patients with high cholesterol met its co-primary endpoints...
23 January 2014 | By Amgen
Study meets co-primary endpoints of LDL cholesterol reduction...
15 January 2014 | By Amgen
Collaboration brings unique expertise together focus is to translate IBD gene and biology findings into potential new treatment options for patients...
1 January 2014 | By Amgen
"The results of the study demonstrate significantly increased BMD and stimulation of bone formation with romosozumab treatment..."
17 December 2013 | By Amgen
Study meets co-primary endpoints of LDL cholesterol reduction...
22 November 2013 | By Amgen
First and only FDA-approved treatment option for patients with this type of thyroid cancer...
20 November 2013 | By Amgen
Data presented at American Heart Association Scientific sessions 2013 and simultaneously published in circulation...
18 November 2013 | By Amgen
Differences in survival rates were pronounced in the subset of patients with stage IIIB, IIIC or IV M1a disease...
14 November 2013 | By Amgen
First long-term data of a PCSK9 Inhibitor to be featured in clinical science: special reports session...
7 November 2013 | By Amgen
Innovative program - Amgen Biotech Experience - brings real-world biotechnology lab experience to students...
In this Raman spectroscopy In-Depth Focus: Raw material identification using dual laser handheld Raman spectroscopy; Raman spectroscopy in support of biotherapeutic production: applications in protein formulation and purification; Raman Spectroscopy Roundtable...
24 October 2013 | By Amgen
McNamee will be responsible for leading a series of multi-year initiatives aimed at delivering growth and increasing productivity...
16 October 2013 | By Amgen
Mr. Garland will serve on the Governance and Nominating Committee and the Audit Committee of the Board...
4 October 2013 | By Amgen
Prolia open-label extension trial showed continued increases in bone mineral density and low fracture incidence for up to eight years...
